A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma
KCP-330-017 (STOMP)
NCT02343042
Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
L'HOTEL-DIEU DE QUEBEC ET CRCEO
|
Myeloma |
Dr. Marc Lalancette
Diane Bernard
418-525-4444 poste 15782 Patricia Chabot
418-525-4444 poste 15769
|
A Phase 1/2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple Myeloma
M15-654
NCT03314181
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Myeloma |
Dr. Chaim Shustik
Dr. Michael Sebag
Nancy Renouf
514-934-1934 poste 35718
|
The Terry Fox Pan-Canadian Multiple Myeloma Molecular Monitoring Study
NCI M4
NCT03421132
Recruiting
|
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX
|
Myeloma |
Dr. Richard Leblanc
Nathalie Lachapelle
514-252-3400 poste 4471
|
A Phase 3 Randomized, Open Label, Multicenter Study of Isatuximab (SAR650984) in Combination With Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With High-risk Smoldering Multiple Myeloma
ITHACA
NCT04270409
Recruiting
|
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX
|
Myeloma |
Dr. Richard Leblanc
Marie-Pier Lecours-Cyr
514-252-3400 poste 5037 Nathalie Lachapelle
514-252-3400 poste 4471
|
A Randomized, 2-Arm, Phase 3 Study of Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease-Positive After Undergoing Autologous Stem-Cell Transplantation
MagnetisMM-7 (C1071007)
NCT05317416
Recruiting
|
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX
|
Myeloma |
Dr. Richard Leblanc
Nathalie Lachapelle
514-252-3400 poste 4471
|
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
EFC15951
NCT05405166
Recruiting
|
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX
|
Myeloma |
Dr. Richard Leblanc
|
A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy After Autologous Stem Cell Transplantation (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (NDMM)
EXCALIBER-Maintenance
NCT05827016
Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
|
Myeloma |
Dr. Marc Lalancette
Philippe Nadeau
418-649-0252 poste 63115
|
A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
AURIGA
NCT03901963
Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
L'HOTEL-DIEU DE QUEBEC ET CRCEO
|
Myeloma |
Dr. Marc Lalancette
Patricia Chabot
418-525-4444 poste 15769
|
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
EFC15951
NCT05405166
Recruiting
|
CISSS DE LA MONTEREGIE-CENTRE
HOPITAL CHARLES-LE MOYNE
|
Myeloma |
Dr. Sabrina Trudel
Christine Giard
450-466-5000 poste 2278
|
A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma
SUCCESSOR-1
NCT05519085
Recruiting
|
CIUSSS DU NORD-DE-L'ILE-DE-MONTREAL
HOPITAL DU SACRE-COEUR-DE-MONTREAL
|
Myeloma |
Dr. Jean-Samuel Boudreault-Pedneault
Marie-Anne Capobianco
514-338-2222 poste 3493
|